RU2546117C2 - СОЕДИНЕНИЯ, ОБЛАДАЮЩИЕ АКТИВИРУЮЩИМ ДЕЙСТВИЕМ НА ПОДТИПЫ РЕЦЕПТОРОВ, АКТИВИРУЕМЫХ ПРОЛИФЕРАТОРОМ ПЕРОКСИСОМ (PPARs), И СПОСОБ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ УКАЗАННЫХ СОЕДИНЕНИЙ - Google Patents

СОЕДИНЕНИЯ, ОБЛАДАЮЩИЕ АКТИВИРУЮЩИМ ДЕЙСТВИЕМ НА ПОДТИПЫ РЕЦЕПТОРОВ, АКТИВИРУЕМЫХ ПРОЛИФЕРАТОРОМ ПЕРОКСИСОМ (PPARs), И СПОСОБ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ УКАЗАННЫХ СОЕДИНЕНИЙ Download PDF

Info

Publication number
RU2546117C2
RU2546117C2 RU2012153702/04A RU2012153702A RU2546117C2 RU 2546117 C2 RU2546117 C2 RU 2546117C2 RU 2012153702/04 A RU2012153702/04 A RU 2012153702/04A RU 2012153702 A RU2012153702 A RU 2012153702A RU 2546117 C2 RU2546117 C2 RU 2546117C2
Authority
RU
Russia
Prior art keywords
compound
formula
subtype
compounds
alkyl
Prior art date
Application number
RU2012153702/04A
Other languages
English (en)
Russian (ru)
Other versions
RU2012153702A (ru
Inventor
Япин Ван
Гоцзюнь ЧЖЭН
Пэн СУНЬ
И Ли
Инцю У
Бинь Лю
Сяоюй ЛЮ
Хуа Бай
Хунянь ЛИ
Сяохэ ЧЖЭН
Original Assignee
Чжэцзян Хисунь Фармасьютикал Ко., Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Чжэцзян Хисунь Фармасьютикал Ко., Лтд. filed Critical Чжэцзян Хисунь Фармасьютикал Ко., Лтд.
Publication of RU2012153702A publication Critical patent/RU2012153702A/ru
Application granted granted Critical
Publication of RU2546117C2 publication Critical patent/RU2546117C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/24—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
RU2012153702/04A 2010-06-18 2011-06-18 СОЕДИНЕНИЯ, ОБЛАДАЮЩИЕ АКТИВИРУЮЩИМ ДЕЙСТВИЕМ НА ПОДТИПЫ РЕЦЕПТОРОВ, АКТИВИРУЕМЫХ ПРОЛИФЕРАТОРОМ ПЕРОКСИСОМ (PPARs), И СПОСОБ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ УКАЗАННЫХ СОЕДИНЕНИЙ RU2546117C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201010202120.1 2010-06-18
CN201010202120.1A CN102285933B (zh) 2010-06-18 2010-06-18 一种对亚型过氧化物酶增殖物激活受体具有激动作用的化合物、其制备方法和应用
PCT/CN2011/075905 WO2011157227A1 (zh) 2010-06-18 2011-06-18 一种对亚型过氧化物酶增殖物激活受体具有激动作用的化合物、其制备方法和应用

Publications (2)

Publication Number Publication Date
RU2012153702A RU2012153702A (ru) 2014-07-27
RU2546117C2 true RU2546117C2 (ru) 2015-04-10

Family

ID=45332709

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2012153702/04A RU2546117C2 (ru) 2010-06-18 2011-06-18 СОЕДИНЕНИЯ, ОБЛАДАЮЩИЕ АКТИВИРУЮЩИМ ДЕЙСТВИЕМ НА ПОДТИПЫ РЕЦЕПТОРОВ, АКТИВИРУЕМЫХ ПРОЛИФЕРАТОРОМ ПЕРОКСИСОМ (PPARs), И СПОСОБ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ УКАЗАННЫХ СОЕДИНЕНИЙ

Country Status (7)

Country Link
US (1) US9346770B2 (zh)
EP (1) EP2583968B1 (zh)
JP (1) JP6092101B2 (zh)
CN (2) CN102285933B (zh)
BR (1) BR112012031867A2 (zh)
RU (1) RU2546117C2 (zh)
WO (1) WO2011157227A1 (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102285933B (zh) * 2010-06-18 2016-03-09 浙江海正药业股份有限公司 一种对亚型过氧化物酶增殖物激活受体具有激动作用的化合物、其制备方法和应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1666472A1 (en) * 2003-09-22 2006-06-07 Ono Pharmaceutical Co., Ltd. Phenylacetic acid derivative, process for producing the same, and use
RU2296754C2 (ru) * 2002-08-30 2007-04-10 Ф.Хоффманн-Ля Рош Аг НОВЫЕ СОЕДИНЕНИЯ 2-АРИЛТИАЗОЛА В КАЧЕСТВЕ АГОНИСТОВ PPAR α И PPAR γ

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9914977D0 (en) * 1999-06-25 1999-08-25 Glaxo Group Ltd Chemical compounds
WO2003072102A1 (en) * 2002-02-25 2003-09-04 Eli Lilly And Company Peroxisome proliferator activated receptor modulators
TWI343915B (en) 2002-10-07 2011-06-21 Hoffmann La Roche Chirale ppar agonists
CN1882553A (zh) * 2003-09-22 2006-12-20 小野药品工业株式会社 苯乙酸衍生物、其生产方法和用途
ES2299906T3 (es) * 2003-11-25 2008-06-01 Eli Lilly And Company Moduladores de receptores activados por proliferadores de peroxisomas.
CN101296892A (zh) * 2005-09-07 2008-10-29 普莱希科公司 Ppar活性化合物
AU2006287521A1 (en) 2005-09-07 2007-03-15 Plexxikon, Inc. PPARactive compounds
WO2007056366A2 (en) * 2005-11-07 2007-05-18 Irm Llc Compounds and compositions as ppar modulators
GB2460784A (en) 2007-03-07 2009-12-16 Dong A Pharmtech Co Ltd Novel phenylpropionic acid derivatives as peroxisome proliferator-activated gamma receptor modulators,method of the same,and pharmaceutical composition
CN102285933B (zh) * 2010-06-18 2016-03-09 浙江海正药业股份有限公司 一种对亚型过氧化物酶增殖物激活受体具有激动作用的化合物、其制备方法和应用

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2296754C2 (ru) * 2002-08-30 2007-04-10 Ф.Хоффманн-Ля Рош Аг НОВЫЕ СОЕДИНЕНИЯ 2-АРИЛТИАЗОЛА В КАЧЕСТВЕ АГОНИСТОВ PPAR α И PPAR γ
EP1666472A1 (en) * 2003-09-22 2006-06-07 Ono Pharmaceutical Co., Ltd. Phenylacetic acid derivative, process for producing the same, and use

Also Published As

Publication number Publication date
JP2013528628A (ja) 2013-07-11
CN102933580A (zh) 2013-02-13
US20130089613A1 (en) 2013-04-11
EP2583968B1 (en) 2016-08-17
JP6092101B2 (ja) 2017-03-08
WO2011157227A1 (zh) 2011-12-22
EP2583968A1 (en) 2013-04-24
CN102285933B (zh) 2016-03-09
US9346770B2 (en) 2016-05-24
CN102285933A (zh) 2011-12-21
BR112012031867A2 (pt) 2016-11-08
EP2583968A4 (en) 2013-10-02
RU2012153702A (ru) 2014-07-27
CN102933580B (zh) 2015-07-01

Similar Documents

Publication Publication Date Title
KR101106631B1 (ko) 대사 질환의 치료용 화합물
CA2627363C (en) Compounds for the treatment of insulin resistance syndrome and diabetes
ES2316736T3 (es) Moduladores de receptores activados por proliferador de peroxisoma.
JP4691619B2 (ja) アルコキシ基を有するレキシノイド化合物
JP2009509932A (ja) Ｐｐａｒ活性化合物
JPWO2006059744A1 (ja) ペルオキシソーム増殖剤活性化受容体δの活性化剤
FR2890072A1 (fr) Nouveaux composesde pyrrolopyridine
FR2787789A1 (fr) Benzopyranes et benzoxepines utilisables dans le traitement de dyslipidemies, de l'atherosclerose et du diabete, compositions pharmaceutiques les contenant et procedes de preparations
JPWO2008016175A1 (ja) ペルオキシソーム増殖剤活性化受容体の活性化剤
KR20070053622A (ko) ＰＰＡＲγ와 ＰＰＡＲα의 활성을 항진시키는 신규화합물, 그것의 제조방법및 그것을 함유한 약제 조성물
WO2004071509A1 (ja) オリゴデンドロサイト分化促進剤
JP5710480B2 (ja) ペルオキシソーム増殖物質活性化受容体サブタイプδに対するアゴニスト作用を有する化合物、その調製方法及びその使用
RU2721283C2 (ru) Замещенные бициклические гетероарильные соединения в качестве агонистов rxr
EA004676B1 (ru) Конденсированные соединения азола и их применение в качестве гипогликаемических агентов
KR20060066730A (ko) 대사 질환의 치료용 화합물
US7375124B2 (en) Use of α-phenylthiocarboxylic and α-phenyloxycarboxylic acids with serum-glucose-lowering and serum-lipid-lowering activity
RU2546117C2 (ru) СОЕДИНЕНИЯ, ОБЛАДАЮЩИЕ АКТИВИРУЮЩИМ ДЕЙСТВИЕМ НА ПОДТИПЫ РЕЦЕПТОРОВ, АКТИВИРУЕМЫХ ПРОЛИФЕРАТОРОМ ПЕРОКСИСОМ (PPARs), И СПОСОБ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ УКАЗАННЫХ СОЕДИНЕНИЙ
Cai et al. Synthesis and evaluation of azaindole-α-alkyloxyphenylpropionic acid analogues as PPARα/γ agonists
EP1266888A1 (en) Quinoline derivatives and medicinal use thereof
US10800726B2 (en) Rexinoid compounds and methods of using rexinoid compounds for treating metabolic disorders and cancer
KR100864677B1 (ko) 항비만 효과를 나타내는 3,5-디히드록시벤조산 유도체화합물 및 이의 제조방법
EA039833B1 (ru) Агонисты ppar, соединения, фармацевтические композиции и способы их применения
CN102863436A (zh) 噻唑烷二酮类衍生物及其制备和用途

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20190619